Mechanism of Action
12.1 Mechanism of Action The antithrombotic action of AGGRENOX is the result of the additive antiplatelet effects of dipyridamole and aspirin. Dipyridamole Dipyridamole inhibits the uptake of adenosine into platelets, endothelial cells and erythrocytes in vitro and in vivo ; the inhibition occurs…
Clinical Trials (5)
Aggrenox To Treat Acute Covid-19
Drug-drug Interaction Study of Aggrenox and Omeprazole in Normal Volunteers
EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA
JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme
Bioequivalence of a New Asasantin Formulation Extended Release (ER) Compared to the Commercially Available Asasantin Formulation (Aggrenox®; Extended Release) in Healthy Male and Female Volunteers